Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Trial ID or NCT#
NCT05224661
Status
RECRUITING
Purpose
Prospective determination of the clinical utility of measurable residual disease (MRD) testing for relapse and survival of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (alloHCT).
Official Title
Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events
Investigator(s)
Lori Muffly
Hematologist,
Blood and marrow transplant specialist,
Blood and marrow transplant specialist,
Hematologist-Oncologist
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Contact us to find out if this trial is right for you.
Contact
Audrey Xu
650-725-1647
View on ClinicalTrials.gov
